A Randomized,Double-blind,Placebo-controlled,Single-ascending Dose Phase Ia Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of STSA-1002 Following Intravenous Infusion in Healthy Subjects
Latest Information Update: 14 Apr 2022
At a glance
- Drugs STSA-1002 (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Staidson Beijing BioPharmaceuticals
- 07 Apr 2022 Status changed from recruiting to completed.
- 29 Sep 2021 Status changed from not yet recruiting to recruiting.
- 09 Sep 2021 New trial record